Reports Q3 revenue $2.217M vs $2.367M last year. “Our third quarter results reflect disciplined execution and meaningful progress toward building a more focused, U.S.-driven business,” said John Erb, Chairman and Chief Executive Officer of Nuwellis (NUWE). “We continue to strengthen our leadership in precision fluid management across critical care, pediatrics, and hospital-based outpatient therapy. With the launch of our new 24-hour circuit and successful early hospital-based outpatient treatments, we are expanding how and where Aquadex therapy can be delivered to improve patient outcomes.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUWE:
- Nuwellis receives notice of allowance for U.S. patent on Vivian system
- Nuwellis’ REVERSE-HF Study: A Potential Game-Changer in Heart Failure Treatment
- Nuwellis Appoints John L. Erb as Interim CFO
- Nuwellis Announces ULTRA-Peds Registry Findings
- Nuwellis reports 92% survival in children with AKI in ULTRA-Peds registry